• Developed and implemented clinical utility and validity studies aimed at establishing plasma microbial cell-free DNA sequencing as a diagnostic standard for infectious diseases and as a biomarker of disease progression across multiple indications.• Led the data analysis, interpretation, and reporting for a series of four manuscripts from the PICKUP study, a prospective, observational, multi-center study involving hospitalized adult patients with hematologic malignancies or prior hematopoietic cell transplantation undergoing bronchoscopy to establish the etiology of pneumonia.• Designed, prepared, and initiated study protocols across multiple indications, contributing scientific and clinical expertise to the development of Case Report Forms (CRFs), Informed Consent documents, and training materials.• Collaborated with Key Opinion Leaders (KOLs) to develop study endpoints, eligibility criteria, biomarker strategies, and position the test within current clinical guidelines.

Led scientific and clinical interactions with pharmaceutical partners to implement Phase 1, 2, and 3 drug development protocols. Contributed actively to internal vetting committees and the molecular tumor board, providing insights and expertise in reviewing protocols, informed consent forms, and investigators’ brochures for upcoming sponsored studies. • Served as Principal Investigator for multiple national studies, including Total Cancer Care and RECOVER-19, and as a Co-Investigator for large precision medicine studies. • As Principal Investigator for the Total Cancer Care Protocol, a comprehensive cancer biorepository and data registry study, oversaw 8 work streams (including pathology, lab operations, and data/IT) and successfully completed study initiation for lung cancer. • Designed, wrote, and initiated RECOVER-19, a complex national study involving 1.5 million patients, which led to the local opening of the Janssen ENSEMBLE Ad26.COV2.S vaccine study. Identified the mortality-lowering effect of ondansetron in COVID-19 ICU patients and contributed to uncovering new pathways for increased risk in patients hospitalized with COVID-19 and type 2 diabetes mellitus. • Developed strong partnerships with pharmaceutical companies to advance precision medicine initiatives, including serving as scientific leader for the Syapse-AdventHealth precision oncology collaboration, resulting in a de-identified database with clinical and biomarker data for over 95,000 cancer patients (lung, breast, ovarian, prostate, and pancreatic). • Implemented protocols and tools to enhance the utilization of genomic data for clinical care and biomarker-based clinical trials enrollment. Led an initiative to identify and prioritize patient populations for targeted enrollment in clinical studies for rare diseases. • Led a Phase 4 Real-World Evidence study examining post-marketing drug effectiveness in hepatocellular carcinoma.

• Conducted comprehensive analyses and rigorous evaluations of clinical, functional, segregation, and in-silico evidence to establish associations between genetic variants and diseases or risk phenotypes. • Processed, interpreted, and analyzed genetic variants for rare complex diseases, metabolic disorders, and cancers using various DNA sequencing platforms in a CLIA-certified diagnostics laboratory. • Spearheaded the scientific data curation and pre-classification program for the Variant Sciences team, contributing to the technical development of a novel clinical genetic testing panel for Maturity Onset Diabetes of the Young (MODY).

• Established, for the first time, a link between genetic variation in one-carbon metabolism genes and hepatic epigenomic and transcriptomic changes in animal models of liver cancer.• Co-designed and published multiple studies investigating hepatic epigenetic markers related to obesity sensitivity, fatty acids, and one-carbon metabolism, and their relationship to hepatocellular carcinoma.

• Designed, conducted, and published a gene-nutrient interaction study demonstrating novel connections between polyunsaturated fatty acid metabolism and the perinatal epigenetic and transcriptomic profiles of the fetal brain and liver in mice.• Identified, through a clinical interventional study, that maternal DNA methylation and genetic variation in the fatty acid desaturase 2 (FADS2) gene are predictors of toddler cognitive performance.

• Trained by rotation in multiple medical specialties as part of the standard curriculum.• Performed diagnostic procedures and provided medical treatment in underserved areas.